Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

What is your approach to maintenance rituximab in patients with IgG4-RD?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · John Hopkins

Since patients can go into a prolonged remission after rituximab induction therapy, I tend to monitor them for signs and symptoms of recurrence before retreating with rituximab. In patients with significant damage from IgG4-RD, such as damage to pancreatic endocrine or exocrine function, I will re-t...

How do you approach using CD 19/20 levels to redose Rituximab for ANCA associated vasculitis?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Mayo Clinic College of Medicine

In the MAINRITSAN 2 trial, a tailored rituximab regimen adapted to ANCA-positivity or ANCA-titre change and/or circulating CD19+ B cell repopulation was compared with fixed-schedule rituximab infusions.There was no significant difference in relapse rates between the fixed-dose and tailored-dose arms...

How do you approach oral DMARD and/or biologic selection in patients with RA and a history of gastric bypass or whom are planning bariatric surgery?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

Very interesting and important question. It is important to remember gastric bypass patients, depending on the type of intervention, can change the absorption of a host of medications, so it is a challenge to know if a lack of response is from poor efficacy or poor absorption, therefore poor bodily ...

How do you recommend tapering IVIG in patients whose inflammatory myositis has achieved remission?

1
4 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

This is a very good question without any right or wrong answer. My practice is to start tapering the IVIG 6 months after the patient has achieved clinical remission. I usually start decreasing the dose of the IVIG, but the other option is to extend the interval between the patient's infusions. The e...

How would you approach a low to moderate titer of one of the APLS antibodies in a patient with a strong family history but no personal history of thrombosis?

2 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

I would repeat these tests in about 12 weeks or so. Certain infections can transiently induce positive antiphospholipid antibodies, usually non-pathogenic, with certain exceptions.

How would you counsel a patient with active SLE on treatment, low to moderate level of one of the APLS antibodies, and remote history of provoked blood clot regarding perioperative anticoagulation?

2 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

Without knowing more specific details, my approach would be to repeat the full panel of antiphospholipid antibodies, institute treatment with HCQ if not there already, discontinue all estrogen products and counsel the patient against smoking. I would coordinate perioperative anticoagulation with a h...

Are there any major differences in clinical manifestations or autoantibody profiles in children with SLE based on ethnicity?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Harvard Medical School

While there is some published data, including those from the Toronto pediatric lupus cohort (Hiraki et al., PMID 19833755), that suggest the prevalence of severe organ manifestations such as nephritis and central nervous system involvement may vary by race or ethnicity, it is difficult to know how d...

What are some explanations for the persistent renal outcome disparity gaps affecting certain minority groups of patients with pediatric SLE despite improvement in overall renal outcomes?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Northwestern University

There are likely some genetic causes, for example, Blazer et al., PMID 33461980 have shown in a Ghanian cohort of patients with SLE that apolipoprotein 1 risk variants are associated with progressive renal failure. However, it is undeniable that in the US, children in minoritized groups are dispropo...

Do you typically see peripheral neuropathy in patients with castleman syndrome?

1
2 Answers

Mednet Member
Mednet Member
Neurology · Cedars-Sinai Medical Center

Castleman's is a rare disorder. It has been associated with POEMS in which severe neuropathy is part of the syndrome, but is not as common an association as myeloma. But neurologists only see the patients who have neurologic symptoms. My brief look at review articles on Castleman's suggests that POE...

Would you consider re-irradiation for recurrence of Dupuytren's Contracture?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Weatherby Health Care

I have, in fact, re-treated one patient about two years after the first course because some nodules were progressing. I did a limited electron field with bolus to cover just the affected area and gave 200 x 10. Things seemed to stabilize after that. I would not treat a third time, however, but I hav...